Shinji Furuzono

Title: The Innovations of Shinji Furuzono

Introduction

Shinji Furuzono is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of bispecific antibodies. With a total of 2 patents, his work has the potential to impact cancer treatment significantly.

Latest Patents

Furuzono's latest patents focus on bispecific antibodies that can serve as anti-tumor agents. One of his inventions describes an antibody that comprises a heavy chain CDRH1 consisting of SEQ ID NO: 54, a heavy chain CDRH2 consisting of SEQ ID NO: 55, and a heavy chain CDRH3 consisting of SEQ ID NO: 56. Additionally, it includes a light chain CDRL1 consisting of SEQ ID NO: 57 or a variant thereof, along with other specific sequences that enhance its efficacy as an anti-tumor agent.

Career Highlights

Throughout his career, Shinji Furuzono has worked with esteemed institutions such as Mie University and Daiichi Sankyo Company, Limited. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research in the field of antibodies.

Collaborations

Furuzono has collaborated with notable colleagues, including Hiroshi Shiku and Yasushi Akahori. These partnerships have fostered an environment of innovation and have led to advancements in their shared field of research.

Conclusion

Shinji Furuzono's contributions to the development of bispecific antibodies highlight his role as a significant inventor in the biotechnology sector. His work continues to pave the way for advancements in cancer treatment and showcases the importance of innovation in medicine.